Ophthalmology · Hollywood, FL
NPI
1356720395
Since 2015
Specialty
Ophthalmology
Code 207W00000X
Group practices
3
Medicare group memberships
Hospitals
1
Hospital affiliations
300 S Park Rd Ste 300
Hollywood, FL, 33021
Phone (954) 925-2740
Groups this clinician bills Medicare through
Medicare paid, 2024
$668K
8,710 services
Medicare patients, 2024
409
Average age 76
Drug cost, 2024
$1.9M
1,224 prescriptions
Company payments, 2025
$929
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Akintomide Apara was code J2777 (injection, faricimab-svoa, 0.1 mg), 4,860 times for 20 patients. In total Akintomide Apara billed 8,710 services in 33 codes, and Medicare paid $668K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-04-30.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J2777 Injection, faricimab-svoa, 0.1 mg | Office | 4,860 | 20 | $27.64 | $134K |
| 92134 Computerized Ophthalmic Imaging | Office | 707 | 383 | $29.55 | $21K |
| J0177 Injection, aflibercept hd, 1 mg | Office | 664 | 25 | $264.30 | $175K |
| 92250 Angiography | Office | 458 | 361 | $27.57 | $13K |
| 67028 Intravitreal Injection | Office | 296 | 79 | $97.35 | $29K |
| 99213 Office E&M - Established | Office | 232 | 123 | $72.91 | $17K |
| J0178 Injection, aflibercept, 1 mg | Office | 212 | 29 | $662.46 | $140K |
| 99214 Office E&M - Established | Office | 200 | 193 | $99.70 | $20K |
| 92014 Ophthalmological E&M | Office | 188 | 182 | $79.34 | $15K |
| 92012 Ophthalmological E&M | Office | 186 | 99 | $58.84 | $11K |
| 92273 Test - Miscellaneous | Office | 55 | 55 | $98.14 | $5,398 |
| 92201 Ophthalmological E&M | Office | 49 | 45 | $18.15 | $889 |
By year: 2022 $534K for 3,317 services; 2023 $611K for 8,835 services; 2024 $668K for 8,710 services.
Medicare prescription drug claims, 2024
In 2024, the drug Akintomide Apara prescribed most often to Medicare patients was Eylea (Aflibercept), with 390 prescriptions and refills. In total Akintomide Apara wrote 1,224 Medicare prescriptions that cost $1.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eylea Aflibercept | 390 | 394 | 110 | $928K |
| Eylea Hd Aflibercept | 140 | 140 | 38 | $447K |
| Vabysmo Faricimab-Svoa | 109 | 109 | 25 | $319K |
| Prednisolone Acetate Generic | 87 | 132 | 47 | $3,757 |
| Ketorolac Tromethamine Generic | 83 | 94 | 28 | $1,774 |
| Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat | 58 | 134 | 23 | $567 |
| Moxifloxacin Moxifloxacin Hcl | 51 | 52 | 37 | $1,203 |
| Ozurdex Dexamethasone | 45 | 135 | 18 | $81K |
| Atropine Sulfate Generic | 25 | 30 | 23 | $938 |
| Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha | 25 | 26 | 23 | $286 |
| Bromfenac Sodium Generic | 23 | 24 | Under 11 | $3,518 |
| Ilevro Nepafenac | 22 | 32 | Under 11 | $9,694 |
| Prolensa Bromfenac Sodium | 20 | 32 | Under 11 | $7,082 |
| Latanoprost Generic | 18 | 32 | Under 11 | $144 |
| Eplerenone Generic | 13 | 25 | Under 11 | $2,081 |
Brand drugs: 896 claims; generic drugs: 328 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Akintomide Apara $929 ($929 in general payments such as food, travel and fees) from 10 companies. The largest payer was Regeneron Healthcare Solutions, Inc. with $409.
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. REGN | 9 | $409 |
| Abbvie Inc. ABBV | 5 | $123 |
| Mallinckrodt Hospital Products Inc. | 4 | $107 |
| Harrow Eye, LLC | 2 | $68.86 |
| Apellis Pharmaceuticals, Inc. APLS | 2 | $56.64 |
| Genentech USA, Inc. ROG.SW | 2 | $47.83 |
| Astellas Pharma US Inc 4503.T | 2 | $42.38 |
| Amgen Inc. AMGN | 2 | $36.82 |
| Neurotech Pharmaceuticals, Inc. | 1 | $21.57 |
| Bausch & Lomb Americas Inc. BLCO | 1 | $14.36 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.